Home > Press > ViRexx Announces Results of Rights Offering and Failure of LM Funds Corp. to Provide Standby Commitment
Abstract:
ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living announces that LM Funds Corp., the standby guarantor under its previously announced rights offering, has failed to fulfill its obligation to provide $3,000,000 CA as the Standby Purchaser for the rights offering.
ViRexx Announces Results of Rights Offering and Failure of LM Funds Corp. to Provide Standby Commitment
Edmonton, AB, Canada | Posted on September 10th, 2008
The Company received 13,244,367 valid tenders for common shares from shareholders who exercised their basic subscription privilege and received 834,535 valid tenders for common shares from shareholders who exercised their additional subscription privilege. In total 14,078,902 rights were exercised which provided gross proceeds to the Company of $633,550.59 CA.
LM Funds Corp. failed to meet its obligation to provide the Standby Commitment of $3,000,000 CA and has notified the Company that it will not meet this obligation. Management is working with its advisors to examine the Company's alternatives in order to determine the appropriate course of action and to attempt to find alternative funding.
"Although we are very disappointed by LM Funds Corp.'s inability to meets its obligation we are encouraged by the number of shareholders who participated in the rights offering", said Darrell Elliott, Chairman and Interim Chief Executive Officer of ViRexx. "We will continue to work closely with our advisors to take appropriate actions where necessary in order to meet the Company's strategic objectives."
If alternative, equivalent financing to replace the LM Funds Corp. commitment is not arranged by close of business on September 18, 2008 shareholders who exercised their rights and wish to rescind their participation in the rights offering will have the opportunity to do so once the appropriate rescission process is determined.
####
About ViRexx Medical Corp.
ViRexx is a Canadian-based development-stage biotech company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Our platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
The TSX has not approved or disapproved of the information contained herein.
For more information, please click here
Contacts:
ViRexx Medical Corp.
Darrell Elliott
Chairman and Chief Executive Officer
(780) 433-4411
(780) 436-0068 (FAX)
or
ViRexx Medical Corp.
Brent Johnston
Chief Financial Officer
(780) 433-4411
(780) 436-0068 (FAX)
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Whirlpools on the Nanoscale Could Multiply Magnetic Memory: At the Advanced Light Source, Berkeley Lab scientists join an international team to control spin orientation in magnetic nanodisks May 22nd, 2013
Bacterial spare parts filter antibiotic residue from groundwater May 22nd, 2013
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Atomic-Scale Investigations Solve Key Puzzle of LED Efficiency: MIT and Brookhaven Lab scientists use electron microscopy imaging techniques to settle a solid-state controversy and raise new experimental possibilities May 22nd, 2013
VC/Funding/Angel financing/Loans/Leases
INSCX™ exchange announces substantial increase in capital designated to provide Trade Finance for registered Nanomaterial Producers May 21st, 2013
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanostart-holding New Asia Investments invests in breakthrough water projects May 13th, 2013
Nanomedicine
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Announcements
Whirlpools on the Nanoscale Could Multiply Magnetic Memory: At the Advanced Light Source, Berkeley Lab scientists join an international team to control spin orientation in magnetic nanodisks May 22nd, 2013
Bacterial spare parts filter antibiotic residue from groundwater May 22nd, 2013
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Atomic-Scale Investigations Solve Key Puzzle of LED Efficiency: MIT and Brookhaven Lab scientists use electron microscopy imaging techniques to settle a solid-state controversy and raise new experimental possibilities May 22nd, 2013